Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive

Table 1: Percentage of IgG Positive EBV Patients Between Patients Treated with anti-TNF Agents (Cases) and Controls

	Treated with Biologic (Anti-TNF)		Biologic Naive		p-Value
	n	IgG EBV	n	IgG EBV	p-Value
Entire Study Population	72	90%	50	98%	0.1
RA Only	53	91%	46	98%	0.2
AS Only	6	67%	0	-	-
PsA Only	9	100%	3	100%	-
Other Inflammatory Arthritis Only	4	100%	1	100%	-

RA = rheumatoid arthritis, AS = ankylosing spondylitis, PsA = Psoriatic arthritis.